期刊文献+

骨髓增生异常综合征患者血小板减少的预后意义初步研究 被引量:4

A preliminary study of prognostic value of thrombocytopenia in patients with primary myelodysplastic syndromes
原文传递
导出
摘要 目的探讨血小板减少对判断骨髓增生异常综合征(MDS)患者预后的意义。方法回顾性分析419例原发性MDS患者临床资料,应用Kaplan—Meier、Log—rank检验及COX回归模型评估影响预后的因素。结果419例MDS患者中血小板减少(PLT〈10×10^9/L)者256例(61.1%),严重减少(PLT〈30×10^9/L)者103例(24.6%)。PⅡ≥100×10^-9/L组、(50—99)×10^9/L组、(30~49)×10^9/L组和〈30×10^9/L组患者中位生存时间分别为41、38、19和17个月,差异有统计学意义(P=0.000)。单因素分析显示PLT〈30×10^9/L、红细胞平均体积(MCV)≤95fl、LDHI〉300U/L、有淋巴样小巨核细胞、有核红细胞糖原染色(E-PAS)阳性、国际预后积分系统(IPSS)染色体核型预后中等及不良为MDS不良预后因素;WHO分型中难治性血细胞减少伴有多系发育异常(RCMD)、难治性贫血伴有原始细胞过多(RAEB)一I及RAEB-11的患者较其他类型的患者预后差。多因素分析显示PLT〈30×10^9/L,MCV≤95fl,IPSS染色体核型预后中等及不良,WHO分型RCMD、RAEB-I及RAEB-II具有独立预后意义。修订的WHO分型预后积分系统(WPSS)各参数赋值如下:PLT〈30×10^91分,其他0分;MCV≤95fl 1分,其他0分;染色体核型良好0分,中等1分,不良2分;WHO分型中RCMD1分,RAEB—I2分,RAEB一Ⅱ3分,其他0分。患者分为低危(0—1分)、中危-1(2—3分)、中危-2(4—5分)和高危组(6~7分),其中位生存期分别为59、28、14和4个月,各组间差异具有统计学意义(P值均〈0.05)。结论血小板严重减少的MDS患者预后不良,结合血小板计数、染色体核型、MCV及修订的WPSS有望更好地促进我国MDS患者分组治疗策略的制订。 Objective To investigate the prognostic value of thrombocytopenia in patients with pri- mary myelodysplastic syndromes(MDS). Methods Four hundred and nineteen primary MDS patients were retrospectively analyzed. Kaplan-Meier method, Log-rank test and COX regression model were used to evalu- ate factors that influence the prognosis. Results Two hundred and fifty-six cases (61.1% ) had thrombocyto- penia(PLT 〈 100×10^9/L), one hundred and three cases (24.6%) had severe thrombocytopenia(PLT 〈 30 ×10^9/L). Overall survival (OS) tended to shorten along with the decreasing of platelet count. Univariate analysis indicated that PLT 〈 30 ×10^9/L, MCV 〈95 fl, LDH 〉1300 U/L, lymphocyte-like mieromegakaryo- cyte, nucleated RBC PAS positive, IPSS cytogenetic intermediate- and poor-risk were all related with poor prognosis. Moreover, the prognosis of patients with RCMD, RAEB- I or RAEB- lI was poorer than that of the other subgroups. Among these parameters, PLT 〈 30 x 109/L, MCV 〈~95 fl, IPSS cytogenetic intermediate- and poor-risk group and RCMD, RAEB- I and RAEB- II had independent prognostic significance in multiva- riate analysis. Modified WPSS prognostic model was proposed by adopting PLT, MCV, chromosomal karyo- type and WHO classification. The OS of patients with low risk, intermediate-1 risk, intermediate-2 risk and high risk were 59, 28, 14 and 4 months, respectively, and there was a statistically significant difference be- tween the groups ( P 〈 0. 05 ). Conclusion Severe thrombocytopenia indicated unfavorable prognosis, in combination with MCV, chromosomal karyotype and WHO classification, a modified WPSS prognostic model was proposed and worked well for prognostic indication in patients with MDS.
出处 《中华血液学杂志》 CAS CSCD 北大核心 2012年第7期532-535,共4页 Chinese Journal of Hematology
基金 国家自然科学基金(81070403) 天津市科技计划项目(09ZCZDSF03800) 科技部国际合作项目(2010DFB30270)作者单位:通信作者:肖志坚,Email:zjxiao@hotmail.eom
关键词 骨髓增生异常综合征 血小板减少 预后 WHO分型预后积分系统 Myelodysplastic syndromes Thrombocytopenia Prognosis WPSS prognostic sco- rinz svstem
  • 相关文献

参考文献10

  • 1Al Ameri A,Jabbour E,Garcia-Manero G. Significance of thrombocytopenia in myelodysplastic syndromes:associations and prognostic implications[J].Clin Lymphoma Myeloma Leuk,2011.237-241.
  • 2Swerdlow SH,Campo E,Harris NL. WHO classification of Tumours of Haematopoietic and Lymphoid Tissues[M].Lyon:International Agency for Research on Cancer,2008.87-104.
  • 3Cazzola M,Della Porta MG,Travaglino E. Classification and prognostic evaluation of myelodysplastic syndromes[J].Seminars in Oncology,2011.627-634.
  • 4Malcovati L,Germing U,Kuendgen A. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes[J].Journal of Clinical Oncology,2007.3503-3510.
  • 5Malcovati L,Della Porta MG,Strupp C. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System(WPSS)[J].Haematologica,2011.1433-1440.
  • 6Kantarjian H,Giles F,List A. The incidence and impact of thrombocytopenia in myelodysplastic syndromes[J].Cancer,2007.1705-1714.
  • 7Gonzalez-Porras JR,Cordoba I,Such E. Prognostic impact of severe thrombocytopenia in low-risk myelodysplastic syndrome[J].Cancer,2011.5529-5537.
  • 8Kantarjian H,O'Brien S,Ravandi F. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System[J].Cancer,2008.1351-1361.
  • 9Breems DA,Van Putten WL,Huijgens PC. Prognostic index for adult patients with acute myeloid leukemia in first relapse[J].Journal of Clinical Oncology,2005.1969-1978.
  • 10李璘,聂玲,于明华,于阳,刘亮,秦铁军,徐泽锋,张悦,肖志坚.基于常规实验室检查指标的改良WPSS预后积分系统对骨髓增生异常综合征预后判断意义的初步研究[J].中华血液学杂志,2009,30(5):313-317. 被引量:9

二级参考文献10

  • 1于明华,刘世和,邵英起,郝玉书,肖志坚.原发性骨髓增生异常综合征患者染色体核型与IPSS危度分组:FAB与WHO分型比较[J].中华血液学杂志,2004,25(8):482-485. 被引量:12
  • 2肖志坚.骨髓增生异常综合征的诊断和治疗认识现况[J].国际输血及血液学杂志,2007,30(1):1-4. 被引量:9
  • 3Malcovati L, Germing U, Kuendgen A, et al. A WHO classification-based prognostic scoring system (WPSS) for predicting survival in myelodysplastic syndromes. Blood, 2005,106: 788.
  • 4Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood, 2002,100:2292-2302.
  • 5宋玉华.血细胞的组织化学//邓家栋,杨崇礼,杨天楹,等.邓家栋临床血液学.上海:上海科学技术出版社,2001:132-148.
  • 6Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 1997,89:2079-2088.
  • 7Wimazal F, Sperr WR, Kundi M, et al. Prognostic value of lactate dehydrogenase activity in myelodysplastic syndromes. Leuk Res, 2001, 25:287-294.
  • 8Bemasconi P, Klersy C, Boni M, et al. World Health Organization classification in combination with eytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysplastic syndromes. Br J Haematol, 2007,137 : 193-205.
  • 9Tennant GB, Al-Sabah AI, Burnett AK. Prognosis of myelodysplasic patients : non-parametric muhiple regression analysis of populations stratified by mean corpuscular volume and marrow myeloblast number. Br J Haematol, 2002, 119 : 87-96.
  • 10Oguma S, Yoshida Y, Okuma M, et al. Mode of disease progression in primary myelodysplastic syndromes: a Japanese co-operative study. The Refractory Anemia Study Group of The Ministry of Health and Welfare, Japan. Leuk Res, 1997,21:241-247.

共引文献8

同被引文献37

引证文献4

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部